Want to see KR:003090 full AI Analyst Report?
Daewoong Co., Ltd. (003090) Stock Price & Analysis
003090 Stock Chart & Stats
- Day’s Range
- KRW 14,650.00 - KRW 15,310.00
- 52-Week Range
- KRW 14,380.00 - KRW 30,600.00
- Previous Close
- KRW 14,900.00
- Volume
- N/A
- Average Volume (3M)
- 53.77K
- Market Cap
- KRW 617.86B
- Enterprise Value
- KRW 2.01T
- Total Cash (Recent Filing)
- KRW 294.78B
- Total Debt (Recent Filing)
- KRW 974.45B
- Price to Earnings (P/E)
- 3.3
- Beta
- 0.32
- Next Earnings
- Nov 12, 2026 (Est.)
- EPS Estimate
- N/A
- Last Dividend Ex-Date
- Dec 29, 2025
- Dividend Yield
- 1.32%
Bulls Say, Bears Say
Bulls Say
Steady Revenue Growth
Steady revenue expansion, including acceleration in the trailing twelve months, indicates continuing demand for Daewoong’s healthcare portfolio. Consistently strong gross margins also suggest the company retains meaningful product economics that can support reinvestment and profitability as sales grow.
Profitability Recovery
The recovery in net profitability and sustained double-digit returns on equity show that Daewoong can generate attractive earnings from its capital base after the 2024 setback. This improves internal funding capacity and supports a more durable earnings foundation if margins remain stable.
Positive Operating Cash Flow
Positive and improving operating cash flow demonstrates that the underlying business is converting operations into cash, even though investment and working-capital demands remain substantial. Continued operating cash improvement could strengthen funding flexibility if it eventually supports positive free cash flow.
Bears Say
Persistent Negative Free Cash Flow
Persistent negative free cash flow limits the cash available for debt reduction, shareholder returns, and internally funded growth. The pattern also indicates that reinvestment needs or working-capital demands remain high, making stronger cash conversion important to the company’s financial resilience.
Rising Leverage
The upward leverage trajectory reduces financial flexibility and increases the importance of dependable cash generation. Higher debt relative to equity can constrain future capital allocation and leave Daewoong less able to absorb operating pressure while free cash flow remains negative.
Earnings Volatility
The sharp 2024 margin decline and subsequent recovery show that earnings are not yet consistently stable. Slightly lower trailing operating profitability also points to cost pressure despite revenue growth, which could limit the durability of future earnings expansion if it persists.
003090 FAQ
What was Daewoong Co., Ltd.’s price range in the past 12 months?
What is Daewoong Co., Ltd.’s market cap?
When is Daewoong Co., Ltd.’s upcoming earnings report date?
How were Daewoong Co., Ltd.’s earnings last quarter?
Is Daewoong Co., Ltd. overvalued?
Does Daewoong Co., Ltd. pay dividends?
What is Daewoong Co., Ltd.’s EPS estimate?
How many shares outstanding does Daewoong Co., Ltd. have?
What happened to Daewoong Co., Ltd.’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Daewoong Co., Ltd.?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Daewoong Co., Ltd.
Operating alongside its various subsidiaries, Daewoong Co., Ltd. is primarily engaged in the production and sale of pharmaceutical products. Additionally, the company generates income from real estate leasing. Established in 1961, the firm transitioned its name from Daewoong Pharmaceutical Co., Ltd. to its current designation, Daewoong Co., Ltd., in 2002. Its corporate headquarters are located in Seongnam-si, South Korea.
- Sector
- General
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Yeong-Hwan Yoon
- Employees
- 413
- Website
- www.daewoongholdings.com
- Address
- KR
Daewoong Co., Ltd. (003090) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 6 | 11 |
| Technical Analysis | 1 | 6 | 3 |
| Moving Averages | 4 | 0 | 8 |